ZT-01 to prevent nocturnal hypoglycemia
What this study tests
Zucara phase 2a crossover study of ZT-01, described by the sponsor as a somatostatin-receptor antagonist intended to restore glucagon release during lows, for nocturnal hypoglycemia in adults with T1D.
Editorial review: .
Registry checked: 2026-09-17. Registry’s own update: 2026-04-29.
Source dates appear in the references where available; this record has no dated citation metadata.
Trial status, labels and access can change between reviews. How we review the evidence · How to read the evidence
Evidence at a glance
- Who can enter the study?
- Adults 18-75 with T1D and recurrent nocturnal hypoglycemia. Registered eligibility ↗Enrollment criteria describe who may enter. They do not establish who was analyzed or the denominator for a reported result.
- Reported benefit and results
- No results posted. Primary completion expected December 2026; study completion May 2027.Read the result sources and their limitations →
- Important harms
- Read the reported results, safety discussion and original sources. A separate harms summary is not available; this does not establish safety.
- Research access and approval
- Study regions: United States, Canada. A trial listing does not establish product approval or current recruitment at a particular site. Check the study’s current entry requirements.
- What remains uncertain?
- Read the full discussion and original sources for study limitations. Planned endpoints and completion dates are not results.
Research status alone does not establish approval, clinical benefit or local availability.
Primary endpoints
- Rate of nocturnal (midnight to 06:00) hypoglycemic events below 54 mg/dL (3.0 mmol/L) lasting at least 15 minutes, versus placebo
The full picture
This record has no longer discussion. Use the study criteria, reported results and original sources on this page to assess what is known and what remains unresolved.
Sources
- [1]NCT05762107: ZT-01 to prevent nocturnal hypoglycemia · Trial registry